Sign In
Buy ZBIO
$17.40
+0.270 (+1.58%)
At Close: Jun 03, 2026
Insiders Bet Big on These 3 Fintech and Biotech Stocks
08:45am, Friday, 17'th Oct 2025
The big banks have started off the new earnings-reporting season, which means that insider buying of stocks could be muted for a while.
Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948
12:12pm, Thursday, 16'th Oct 2025
Leon O. Moulder, the founder, Chief Executive Officer, and Chairman of the Board of Directors, acquired 36,928 shares of Zenas BioPharma (ZBIO -7.97%) on October 7, 2025, through an open-market purcha
Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal
08:00am, Thursday, 09'th Oct 2025
Zenas BioPharma (ZBIO) secures a $2B licensing deal with InnoCare, expanding its pipeline with orelabrutinib for global non-oncology indications. ZBIO's two late-stage candidates, obexelimab and orela
Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug
06:04am, Wednesday, 08'th Oct 2025
Zenas BioPharma said on Wednesday it has secured global rights to develop and commercialize an experimental drug from China-based InnoCare Pharma for multiple sclerosis and other autoimmune conditions
- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multipl
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
07:05am, Tuesday, 02'nd Sep 2025
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexe
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
07:05am, Tuesday, 26'th Aug 2025
WALTHAM, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
07:05am, Tuesday, 12'th Aug 2025
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -
Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS
01:42pm, Monday, 28'th Jul 2025
Zenas BioPharma, Inc.'s Obexelimab offers a differentiated, non-depleting B-cell inhibition approach, with promising Phase 2 data in IgG4 and upcoming pivotal catalysts in 2025. The lead asset's block
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 20'th Jun 2025
WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader
NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors ar
Investors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)
06:30pm, Monday, 16'th Jun 2025
NEW YORK, NY / ACCESS Newswire / June 16, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
01:25pm, Monday, 16'th Jun 2025
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities law
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
12:47pm, Monday, 16'th Jun 2025
LOS ANGELES--(BUSINESS WIRE)---- $ZBIO--ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
